These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32989241)

  • 1. Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation.
    Lee SH; Kim JM; Lee DG; Lee J; Park JG; Han TS; Cho HS; Cho YL; Bae KH; Park YJ; Lee SJ; Lee MS; Huh YM; Jo DY; Yun HJ; Jeon HJ; Kim N; Joo M; Kim JS; Lee HJ; Min JK
    Cell Death Differ; 2021 Mar; 28(3):968-984. PubMed ID: 32989241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.
    Jin R; Wang X; Zang R; Liu C; Zheng S; Li H; Sun N; He J
    Cancer Lett; 2020 Jul; 483():46-58. PubMed ID: 32272148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Src/Cav1-dependent activation of the EGFR by Dsg2.
    Overmiller AM; McGuinn KP; Roberts BJ; Cooper F; Brennan-Crispi DM; Deguchi T; Peltonen S; Wahl JK; Mahoney MG
    Oncotarget; 2016 Jun; 7(25):37536-37555. PubMed ID: 26918609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
    Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
    Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
    Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of desmoglein 2 promotes EMT progression in gallbladder cancer.
    Wang L; Lv Y; Li J; Nan Y; Piao L; Liang Z
    Histol Histopathol; 2023 Apr; 38(4):467-474. PubMed ID: 36259602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dsg2 via Src-mediated transactivation shapes EGFR signaling towards cell adhesion.
    Ungewiß H; Rötzer V; Meir M; Fey C; Diefenbacher M; Schlegel N; Waschke J
    Cell Mol Life Sci; 2018 Nov; 75(22):4251-4268. PubMed ID: 29980799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling.
    Ye M; Zhang Y; Gao H; Xu Y; Jing P; Wu J; Zhang X; Xiong J; Dong C; Yao L; Zhang J; Zhang J
    Clin Cancer Res; 2018 Mar; 24(5):1227-1239. PubMed ID: 29229632
    [No Abstract]   [Full Text] [Related]  

  • 9. Desulfation of cell surface HSPG is an effective strategy for the treatment of gallbladder carcinoma.
    Yi B; Qiu Y; Ji W; Wei M; Liu C; Peng Z; Zhang Y; Quan Z; Tang Z; Su C
    Cancer Lett; 2016 Oct; 381(2):349-58. PubMed ID: 27502167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
    Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS
    Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
    Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR.
    Zhao S; Cao Y; Liu SB; Wang XA; Bao RF; Shu YJ; Hu YP; Zhang YJ; Jiang L; Zhang F; Liang HB; Li HF; Ma Q; Xu Y; Wang Z; Zhang YC; Chen L; Zhou J; Liu YB
    J Exp Clin Cancer Res; 2016 Jun; 35(1):97. PubMed ID: 27317099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway.
    Shen H; He M; Lin R; Zhan M; Xu S; Huang X; Xu C; Chen W; Yao Y; Mohan M; Wang J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):247. PubMed ID: 31182136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mPRα mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway.
    Lu X; Guan A; Chen X; Xiao J; Xie M; Yang B; He S; You S; Li W; Chen Q
    Mol Carcinog; 2020 Feb; 59(2):179-192. PubMed ID: 31777985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
    Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
    BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.
    Filosto S; Baston DS; Chung S; Becker CR; Goldkorn T
    Mol Cancer Ther; 2013 Aug; 12(8):1579-90. PubMed ID: 23686837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
    Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
    Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
    Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
    Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.